Covid-19: Pfizer announces its vaccine for children aged 5 to 11 years is effective

According to the company, the vaccine offered "a strong response in this group of children after the second dose" and "was also well tolerated, with side effects comparable" to those of older people.

RIO DE JANEIRO, BRAZIL - Pharmaceutical companies Pfizer and BioNTech announced Monday (20) that the results of the latest clinical trials of their Covid-19 vaccine for children aged 5 to 11 years have generated a "robust" antibody response and are safe, bringing closer the possibility of a children's serum available by the end of October.

The tests were conducted on 2,268 participants aged 5 to 11 years with vaccination of two doses, with three weeks between each dose.

The doses used are ten micrograms instead of the 30 micrograms used in the vaccines for those over 12 years . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?